Ardent Health Partners Files S-1/A for Corporate Conversion

TL;DR

Ardent Health Partners is converting to a corporation, filing amended docs with SEC.

AI Summary

Ardent Health Partners, LLC, a healthcare provider, filed an S-1/A amendment on July 8, 2024, to convert into a corporation named Ardent Health Partners, Inc. The filing details their business operations, including general medical and surgical hospital services, and provides contact information for their principal executive offices in Brentwood, Tennessee.

Why It Matters

This filing indicates a significant corporate restructuring for Ardent Health Partners, potentially paving the way for future public offerings or changes in ownership structure.

Risk Assessment

Risk Level: medium — As a healthcare provider undergoing corporate conversion, Ardent Health Partners faces regulatory, operational, and market risks inherent in the healthcare industry and potential public market participation.

Key Numbers

• 333-280425 — SEC Registration Number (Identifies the specific registration for Ardent Health Partners)
• 8062 — SIC Code (Classifies Ardent Health Partners' business as General Medical & Surgical Hospitals)

Key Players & Entities

• Ardent Health Partners, LLC (company) — Registrant
• Ardent Health Partners, Inc. (company) — Name after conversion
• Martin J. Bonick (person) — Chief Executive Officer
• 333-280425 (dollar_amount) — SEC Registration Number
• July 8, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $20.00 — l public offering price will be between $20.00 and $22.00 per share. Following the c
• $22.00 — fering price will be between $20.00 and $22.00 per share. Following the consummation
• $204.0 million — ice buildings to Ventas in exchange for $204.0 million on February 9, 2022, and the concurrent
• $800 billion — ble addressable market size approaching $800 billion. The table below illustrates the calcul

Filing Documents

• d754933ds1a.htm (S-1/A) — 3143KB
• d754933dex21.htm (EX-2.1) — 36KB
• d754933dex34.htm (EX-3.4) — 51KB
• d754933dex35.htm (EX-3.5) — 128KB
• d754933dex41.htm (EX-4.1) — 11KB
• d754933dex51.htm (EX-5.1) — 11KB
• d754933dex106.htm (EX-10.6) — 1231KB
• d754933dex107.htm (EX-10.7) — 53KB
• d754933dex108.htm (EX-10.8) — 24KB
• d754933dex109.htm (EX-10.9) — 1248KB
• d754933dex1010.htm (EX-10.10) — 1328KB
• d754933dex1012.htm (EX-10.12) — 1094KB
• d754933dex1018.htm (EX-10.18) — 67KB
• d754933dex1019.htm (EX-10.19) — 41KB
• d754933dex1020.htm (EX-10.20) — 36KB
• d754933dex1021.htm (EX-10.21) — 34KB
• d754933dex1022.htm (EX-10.22) — 30KB
• d754933dex1023.htm (EX-10.23) — 38KB
• d754933dex1024.htm (EX-10.24) — 38KB
• d754933dex1025.htm (EX-10.25) — 73KB
• d754933dex1029.htm (EX-10.29) — 196KB
• d754933dex1030.htm (EX-10.30) — 84KB
• d754933dex1031.htm (EX-10.31) — 23KB
• d754933dex1032.htm (EX-10.32) — 60KB
• d754933dex1036.htm (EX-10.36) — 73KB
• d754933dex1037.htm (EX-10.37) — 191KB
• d754933dex1038.htm (EX-10.38) — 14KB
• d754933dex1039.htm (EX-10.39) — 126KB
• d754933dex1040.htm (EX-10.40) — 22KB
• d754933dex1041.htm (EX-10.41) — 28KB
• d754933dex1042.htm (EX-10.42) — 35KB
• d754933dex1043.htm (EX-10.43) — 42KB
• d754933dex211.htm (EX-21.1) — 42KB
• d754933dex232.htm (EX-23.2) — 2KB
• d754933dexfilingfees.htm (EX-FILING FEES) — 21KB
• g754933dsp0131a.jpg (GRAPHIC) — 3KB
• g754933dsp0134a.jpg (GRAPHIC) — 4KB
• g754933g01a14.jpg (GRAPHIC) — 56KB
• g754933g01a22.jpg (GRAPHIC) — 186KB
• g754933g0313205813025.jpg (GRAPHIC) — 2KB
• g754933g0620101237512.jpg (GRAPHIC) — 2KB
• g754933g0706031935687.jpg (GRAPHIC) — 2KB
• g754933g0707023531598.jpg (GRAPHIC) — 5KB
• g754933g37z70.jpg (GRAPHIC) — 50KB
• g754933g88g88.jpg (GRAPHIC) — 657KB
• g754933g89g89.jpg (GRAPHIC) — 278KB
• 0001193125-24-176379.txt ( ) — 11372KB

RISK FACTORS

RISK FACTORS 30 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 72

USE OF PROCEEDS

USE OF PROCEEDS 75 DIVIDEND POLICY 76 CAPITALIZATION 77

DILUTION

DILUTION 79 CORPORATE CONVERSION 81

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 83

BUSINESS

BUSINESS 115 MANAGEMENT 156

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 173 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 202 PRINCIPAL STOCKHOLDERS 210

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 212 DESCRIPTION OF CERTAIN INDEBTEDNESS 218 SHARES ELIGIBLE FOR FUTURE SALE 223 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 225

UNDERWRITING

UNDERWRITING 230 LEGAL MATTERS 245 EXPERTS 245 WHERE YOU CAN FIND ADDITIONAL INFORMATION 245 INDEX TO FINANCIAL STATEMENTS F-1 i Table of Contents About this prospectus As used in this prospectus, unless the context otherwise indicates, any reference to Ardent, our Company, the Company, us, we and our refers, prior to the Corporate Conversion (as defined herein), to Ardent Health Partners, LLC, together with its consolidated subsidiaries, and after the Corporate Conversion, to Ardent Health Partners, Inc., the issuer of the shares of common stock offered hereby, together with its consolidated subsidiaries. You should rely only on the information contained in this prospectus or in any free writing prospectus that we authorize to be delivered to you. Neither we nor any of the underwriters have authorized anyone to provide you with additional or different information. If anyone provides you with additional, different or inconsistent information, you should not rely on it. This prospectus is an offer to sell only the shares of common stock offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. You should assume the information contained in this prospectus and any free writing prospectus we authorize to be delivered to you is accurate only as of their respective dates or the date or dates specified in those documents. Our business, financial condition, results of operations or prospects may have changed since those dates. For investors outside the United States : Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus or the offer and sale of the shares of common stock in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offeri

View Full Filing

View this S-1/A filing on SEC EDGAR